Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ORITAVANCIN DIPHOSPHATE vs OXACILLIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ORITAVANCIN DIPHOSPHATE vs OXACILLIN: Safety Overview

Metric	ORITAVANCIN DIPHOSPHATE	OXACILLIN
Total FAERS Reports	276	538
Deaths Reported	4	89
Death Rate	1.4%	16.5%
Hospitalizations	27	254
Average Patient Age	58.5 yrs	46.9 yrs
% Female Patients	39.2%	44.9%
FDA Approval Date	Aug 6, 2014	Approved Prior to Jan 1, 1982
Manufacturer	Melinta Therapeutics, LLC	Eugia US LLC
Route	INTRAVENOUS	INTRAVENOUS
Marketing Status	Prescription	Discontinued